At-home Testing and Preparing for Emerging Strains of COVID-19
Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.
Watch On-Demand Webinar Now
A New Generation of PCR
At-home Testing and Preparing for Emerging Strains of COVID-19 by CoPrimers™
Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.
CRL recently announced a partnership with Walgreens, offering consumers the convenience of self-collecting COVID-19 saliva tests in their own homes without supervision. Dr. Fehling will detail some of the ways she has been able to adapt her labs to usher in a new era of accessible PCR testing.
Accompanying Dr. Fehling will be Masen Christensen, Senior Design Engineer at Co-Diagnostics, who is responsible for ongoing in silico inclusivity and exclusivity analyses used by the CRL/Walgreens partnership and for monitoring all strains and mutations of SARS-CoV-2.
Christensen will summarize the results of these analyses and outline how to achieve high levels of specificity in saliva PCR by virtually eliminating primer-dimers and the necessity for a fluorescent probe by using the CoPrimer structure developed by Co-Diagnostics.
Attendees of this webinar will learn:
- • How Clinical Reference Labs is able to provide non-invasive and highly accurate saliva PCR tests for at-home collection
• The results of ongoing in silico inclusivity and exclusivity analyses on COVID-19 mutations and emerging strains
• How new PCR science and technology is enabling and expanding the applications and accessibility of PCR tests
Dr. Heather Fehling
Chief Scientific Officer
Clinical Reference Laboratory
Dr. Fehling has been with CRL since 2008 and is a certified High Complexity Laboratory Director (HCLD) by the American Board of Bioanalysis (ABB). Dr. Fehling serves as the HCLD for CRL’s Molecular Diagnostics Laboratory, which developed an at-home self-collected saliva test, CRL Rapid Response, that was authorized for emergency use by the FDA in July 2020. More broadly, Dr. Fehling provides scientific leadership across all business units at CRL with extensive experience in laboratory management, new assay development, and business development.

Masen Christensen
Senior Design Engineer
Co-Diagnostics
Masen Christensen works as a senior design engineer for Co-Diagnostics, Inc. He designs and analyzes the company’s Cooperative Primers for human diagnostic, agricultural, and other applications. He designed the SARS-CoV-2 RdRp and E-gene markers and performs ongoing surveillance of their in silico inclusivity and exclusivity.
Masen worked with CoPrimer inventor Brent Satterfield to refine and expand Cooperative Theory mathematics and is an expert on CoPrimer technology.
Understanding CoPrimers™
The unique, proprietary structure of
The CoPrimer™ Binding Process
NO PRIMER DIMERS, NO OPTIMIZATION, REAL MULTIPLEXING
1.
Long PROBE quickly “anchors” bringing the short PRIMER into close proximity with the DNA target
2.
The DNA strands fold, allowing the CoDX™ short primer to bind
3.
When the polymerase extends, the capture (probe) is cleaved, releasing the fluorophore

One of the most important attributes of Co-Diagnostics’ CoPrimer technology is the virtual elimination of “primer-dimers,” the principal source of false positives in diagnostic testing. Primer-dimers are essentially the amplification of errors that can take place during the course of a molecular diagnostic test. These errors dramatically minimize the accuracy of the test and lead to false results and/or inaccurate diagnoses.
The importance of test accuracy cannot be overstated, particularly in a medical diagnostic situation.
The End Result of CoPrimer™ Cooperativity
A Revolutionary Improvement in the
Top Three Objectives of Molecular Diagnostics
1.
Increased
Specificity
2.
Sharper
Sensitivity
3.
Mega
Multiplexing
Creating 80% reduction in research, design and development costs
DISRUPTIVELY AFFORDABLE
The worldwide low-cost leader of
molecular diagnostics services.
Please send me more information about research solutions

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.
COMPANY
LATEST NEWS RELEASE
Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share
Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following the discovery of an incorrectly...
ARCHIVE

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.
Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States
1 (801) 438-1036
COMPANY
© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.